Company intelligence
Curia
From curiosity to cure
About Curia
Curia is a Contract Development and Manufacturing Organization with over 30 years of experience, an integrated network of 25 global sites and 3,500 employees partnering with customers to make treatments broadly accessible to patients. Our biologics and small molecule offering spans discovery through commercialization, with integrated regulatory and analytical capabilities. Our scientific and process experts and state-of-the-art facilities deliver best-in-class experience across drug substance and drug product manufacturing. From curiosity to cure, we deliver every step to accelerate and sustain life-changing therapeutics. To learn more visit us at curiaglobal.com ************************************************** ⚠️NOTICE: Please Be Aware of False Employment Opportunities ************************************************** Please be aware there has been reported fraudulent activity within our industry regarding false offers being made to applicants and requests for personal information from individuals or organizations posing as company representatives. Any applicant who applies to Curia must submit their application through Curia’s career page at https://careers.curiaglobal.com. Applicants will only receive communication, including offer letters, from a curiaglobal.com email address. Please be aware that recent scams used email addresses that are similar to Curia addresses or use other public domain addresses such as gmail.com, yahoo.com and aol.com. Please confirm the sender’s email address prior to sharing your information.
Verified activity
Signals from Curia
10 published signals
Partnerships
Curia was selected by eXoZymes as its commercial-scale manufacturing partner for NCT, with teams in León, Spain, and Rozzano, Italy scaling the proprietary NCT process.
Reported by Curia
Products & Services
Curia published a new resource breaking down how the company helps customers navigate the specific requirements of the MHLW and PMDA, from J-DMF registration through commercial supply.
Reported by Curia
Research & Knowledge
Curia published an article titled A few takeaways from my latest article on the transition from selling to executing in a CDMO partnership.
Reported by Sarah Sink, MBA, MSML
Presence & Recognition
Curia's Drug Product team will be present at Contract Pharma in New Jersey from September 24 to 25 to highlight parenteral Formulation Development expertise and Clinical/Commercial Fill Finish sites.
Reported by David A. Linn
Operations & Supply
Curia provides clients with chemical and analytical development labs, high-potency process development, kilo-scale manufacturing, small-scale GMP manufacturing suites, and stability chambers within one site at the Albany, NY site.
Reported by Curia
Products & Services
Curia offers testosterone base as a steroid hormone API used in transdermal film and extended-release formulations.
Reported by Curia
Presence & Recognition
Curia has a site in Valladolid, Spain, dedicated to steroid chemistry and hormone manufacturing.
Reported by Curia
Operations & Supply
Curia announced the grand opening of its expanded Albuquerque, New Mexico campus, a $200 million investment that strengthens domestic sterile fill-finish manufacturing capacity.
Reported by Curia
Products & Services
Curia has capacity for new mRNA programs in 2026 and 2027, with capabilities spanning mRNA drug substance development, clinical manufacturing, formulation, and fill-finish.
Reported by Curia
Presence & Recognition
Curia is attending two industry events in September, BioProcess International 2026 on Sept. 22-25 and Contract Pharma Contracting & Outsourcing Conference 2026 on Sept. 24-25.
Reported by Curia